BVMed leaflet on apheresis:
This article was originally published in Clinica
The benefits of therapeutic apheresis are described in a new brochure from BVMed, the German industry association for medical devices. The 32-page document describes apheresis as an innovative, extra-corporeal blood filtration procedure for eliminating certain toxins with very few side effects. "Therapeutic apheresis offers many medical disciplines the ability to provide a non-traumatic therapy which can be optimally adapted to the treatment of the individual," says BVMed. The association agreed to represent companies in the area of therapeutic apheresis in November last year (see Clinica No 943, p 6).
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.